title: Mesalamine capsules for the treatment of active Crohn's disease: results of a 16-week trial. Pentasa Crohn's Disease Study Group.
abstract: BACKGROUND
  Mesalamine is released from sulfasalazine in the colon and benefits colonic Crohn's disease. The mesalamine used in this study releases the drug throughout the small bowel and colon. Therefore, this study was designed to detect benefit for Crohn's disease involving the small bowel alone or both the colon and small bowel.
  
  
  METHODS
  This double-blind, randomized, multicenter prospective controlled trial compared placebo and three daily doses of mesalamine in 310 patients. The primary outcome criterion was change in the Crohn's Disease Activity Index (CDAI) from baseline to final study visit.
  
  
  RESULTS
  Patients taking 4 g/day mesalamine experienced a decrease of 72 CDAI points compared with 21 points in the placebo group (P < 0.01). Remission occurred in 43% of the 4-g group and 18% of the placebo group. Patients with ileum-only disease showed a 93-point improvement on 4 g mesalamine, compared with a 2-point improvement in similar patients on placebo. Mesalamine in this trial was not associated with clinically significant toxicity.
  
  
  CONCLUSIONS
  This controlled-release mesalamine preparation is safe and effective at 4 g/day as a single agent in treatment of active Crohn's disease of the ileum and colon.
authors: University of Colorado Health Sciences Center, Denver.
authors: J W
authors: JW
authors: Singleton
authors: S B
authors: SB
authors: Hanauer
authors: G L
authors: GL
authors: Gitnick
authors: M A
authors: MA
authors: Peppercorn
authors: M G
authors: MG
authors: Robinson
authors: L D
authors: LD
authors: Wruble
authors: E L
authors: EL
authors: Krawitt
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000636:Aminosalicylic Acids / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D002214:Capsules; D003424:Crohn Disease / Q000188:drug therapy*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D019804:Mesalamine; D008875:Middle Aged; D011446:Prospective Studies; D012074:Remission Induction; D012720:Severity of Illness Index; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D000636:Aminosalicylic Acids; D002214:Capsules; D019804:Mesalamine